Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial

Esophageal adenocarcinoma (EA) is the sixth most common cause of global cancer death. We rely on endoscopy screening to identify and monitor patients with Barrett’s esophagus (BE) and find neoplastic lesions early enough to manage their EA. This approach has a modest effect on EA supported by low qu...

Full description

Bibliographic Details
Main Authors:	Jankowski, JJ, de Caestecker, JDC, Love, SBL, Reilly, G, Ang, YA, Ragunath, KR, Tucker, AT, Penman, IP, Rodgers, CR, Neale, JN, Roffe, ER, Brooks, CB, Attwood, SA, Morris, DM, Harrison, RH, Bhandari, PB, Watson, PW, Sanders, SS, Barr, HB, Maoayyedi, PM, AspECT Team
Format:	Conference item
Published:	American Society of Clinical Oncology 2018

Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial

Similar Items